Business
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
Five Scientific Publications Underscores Proenzymes as an Effective Tool to Treat and Prevent Metastatic Cancer from Solid Tumors with Further Research in
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nFive Scientific Publications Underscores Proenzymes as an Effective Tool to Treat and Prevent Metastatic Cancer from Solid Tumors with Further Research in Progress\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon, MD, MB, ChB, reflects on the unique anti-cancer effects of PRP discovered as a result of the significant and diligent research invested by the Company and its joint research team over the past decade. PRP is a proenzyme therapy for the treatment and prevention of metastatic cancer from solid tumors. This unique approach could become an effective tool in the fight against metastatic cancer, which is the main cause of patient death for sufferers. PRP is considered unique because rather than kill cancer cells like most standard therapies, proenzymes induce cancer cells to differentiate so they are no longer malignant and die off naturally, “thus preventing these dangerous cells to spread and metastasize,” according to Dr Kenyon.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005483/en/PRP represents a new advancement in the treatment of cancer by inducing cell differentiation, impairing angiogenesis, inhibiting cancer stem cell formation and blocking the EMT process. (Graphic: Business Wire)\nSince 2013, Dr Kenyon and his joint research team have published five scientific papers highlighting the effects of proenzymes against a range of solid tumors, by inducing cell differentiation (reversing cancerous cells so they are no longer malignant), impairing angiogenesis (blood vessel formation) of solid tumors, and inhibiting cancer stem cell (CSC) formation by blocking the epithelial to mesenchymal (EMT) process. The EMT is a normal biological process normally associated with embryogenesis and wound healing. When CSCs undergo the EMT process, they become motile and invasive, with an ability to spread into surrounding tissues. Furthermore, they become immortal and are resistant to standard treatment approaches, which can often cause a patient to relapse post treatment.\n\n“Since our first peer re...